Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuromyelitis Optica (Devic’s Syndrome) - Overview
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
Accendatech Au Pty Ltd
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Apsara Therapeutics
Bio-Thera Solutions Ltd
Biogen Inc
Bionure Farma SL
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Endece LLC
EnhanX Biopharm Inc
Ferring Intertiol Center SA
H. Lundbeck AS
Hall Biopharma Co Ltd
ImCyse SA
Imstem Biotechnology Inc
LFB SA
Mitsubishi Tabe Pharma Corp
NovelMed Therapeutics Inc
Orion BioScience Inc
Thelial Technologies SA
Tolerion Inc
Viela Bio Inc
Yantai RC-Pharmaceutical Co Ltd
Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1511 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAT-4406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BN-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cladribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD19 and CD20 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit C3 and C5 for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-3921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olamkicept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORNx-KI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptide for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
satralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Neuromyelitis Optica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telitacicept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
The-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-3052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ublituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products
Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: FDA and EMA agree to review Roche’s satralizumab applications
Sep 12, 2019: Roche’s drug mitigates relapse risk in late-stage study for NMOSD
Sep 09, 2019: Viela Bio announces data presentations at the 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
Sep 06, 2019: Viela Bio announces publication in The Lancet of pivotal study results of Inebilizumab in patients with Neuromyelitis Optica Spectrum Disorder
Sep 04, 2019: Genentech to present pivotal data for Satralizumab in Neuromyelitis Optica Spectrum Disorder at ECTRIMS
Sep 04, 2019: Roche to present data for satralizumab in neuromyelitis optica spectrum disorder at ECTRIMS
Aug 28, 2019: Alexion announces upcoming data presentations at 35th Congress of the European Committee for treatment and research in Multiple Sclerosis
Aug 27, 2019: European Commission approves SOLIRIS (eculizumab) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Aug 27, 2019: Viela Bio announces U.S. FDA accepts for review Inebilizumab biologics license application for neuromyelitis Optica spectrum disorder
Jul 26, 2019: Alexion receives positive CHMP Opinion for SOLIRIS (Eculizumab) for the treatment Of NMOSD
Jun 28, 2019: FDA approves Alexion’s Soliris as first treatment for CNS disease NMOSD
May 07, 2019: Viela Bio presents pivotal study results of Inebilizumab in patients with neuromyelitis optica spectrum isorder in a plery session at the American Academy of Neurology Annual Meeting
May 03, 2019: New England Jourl Of Medicine publishes positive phase 3 PREVENT data for SOLIRIS (Eculizumab) in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 29, 2019: Genentech to present on Satralizumab at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Apr 18, 2019: Viela Bio receives U.S. FDA Breakthrough Therapy Desigtion for Inebilizumab for treatment of Neuromyelitis Optica Spectrum Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accendatech Au Pty Ltd, H2 2019
Table 12: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ahead Therapeutics SL, H2 2019
Table 13: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Table 14: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apsara Therapeutics, H2 2019
Table 15: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H2 2019
Table 16: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H2 2019
Table 17: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma SL, H2 2019
Table 18: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 19: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chord Therapeutics Sarl, H2 2019
Table 20: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Table 21: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Cour Pharmaceuticals Development Co Inc, H2 2019
Table 22: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Endece LLC, H2 2019
Table 23: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by EnhanX Biopharm Inc, H2 2019
Table 24: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ferring International Center SA, H2 2019
Table 25: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by H. Lundbeck AS, H2 2019
Table 26: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Table 27: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by ImCyse SA, H2 2019
Table 28: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Imstem Biotechnology Inc, H2 2019
Table 29: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB SA, H2 2019
Table 30: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
Table 31: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by NovelMed Therapeutics Inc, H2 2019
Table 32: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Orion BioScience Inc, H2 2019
Table 33: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Thelial Technologies SA, H2 2019
Table 34: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Tolerion Inc, H2 2019
Table 35: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Viela Bio Inc, H2 2019
Table 36: Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
Table 37: Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2019
Table 38: Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, H2 2019